|Bid||19.98 x 900|
|Ask||20.04 x 900|
|Day's Range||19.48 - 20.40|
|52 Week Range||9.01 - 20.40|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.25|
During Q4, Aerie Pharmaceuticals's (NASDAQ:AERI) reported sales totaled $24.68 million. Despite a 5.92% in earnings, the company posted a loss of $35.59 million. Aerie Pharmaceuticals collected $20.08 million in revenue during Q3, but reported earnings showed a $33.60 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Aerie Pharmaceuticals posted an ROCE of -1.49%. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. View more earnings on AERI ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Aerie Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth. In Aerie Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions. Q4 Earnings Insight Aerie Pharmaceuticals reported Q4 earnings per share at $-0.79/share, which did not meet analyst predictions of $-0.73/share. See more from BenzingaClick here for options trades from BenzingaReturn On Capital Employed Overview: SnapWhy Is It Moving? Looking Into Why Airbnb's Stock is Trading Lower Today© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.
Shares of Aerie Pharmaceuticals surged 16.3% on Feb. 26 after the ophthalmic pharmaceutical company’s 4Q revenue topped the Street’s estimates. Revenue in the fourth quarter surged 23% sequentially to $24.7 million and handily exceeded analysts’ expectations of about $22.36 million. The top-line growth reflected “strong sequential volume growth in our glaucoma franchise and increased net revenue per bottle,” said Aerie (AERI) CEO Vicente Anido. Wholesaler shipments jumped 18% sequentially in 4Q. Anido further added, “We expect our net revenue per bottle to continue increasing as we proceed through 2021.” (See Aerie Pharmaceuticals stock analysis on TipRanks) The pharma company reported a 4Q loss of $1 per share, which narrowed from the year-ago period’s loss of $1.21 per share. Analysts had estimated a smaller loss of $0.73 per share. Aerie has a collaboration with Santen and its first Phase 3 trial for Rhopressa is ongoing in Japan. With regulatory approval for its 2 glaucoma products (Rhopressa and Rocklatan) and positive results from Mercury 3 trial, the company is seeing interest from potential collaborators in Europe. Following the financial results, Mizuho Securities analyst Difei Yang reiterated a Buy rating and a price target of $28 (52.3% upside potential) on the stock. Yang said, “Aerie’s strong 4Q results underscore its growing operating momentum. Quarterly net pricing increased from $77 to $80 sequentially, and we forecast further gains, projecting a net price per bottle of $82 in 2021.” Yang added “The company continues to receive inbound European partnership interest, and a partnership announcement in the region could act as a positive catalyst.” Turning now to the rest of Wall Street, Aerie scores a Strong Buy consensus rating based on 3 Buys and 1 Hold. The average analyst price target of 26.67 implies about 45% upside from current levels. That’s after shares already rallied more than 41% over the past three months. Related News: LHC Group Slips 5.9% After-Hours On Tepid 1Q Outlook Arcosa’s 2021 Revenue Outlook Disappoints After 4Q Miss; Stock Plunges 16% Clear Channel Posts Better-Than-Expected Sales; Shares Surge More recent articles from Smarter Analyst: Airbnb Beats 4Q Sales, Sees Booking Demand Picking Up; Shares Pop 13% DoorDash Loss More Than Doubles On IPO Related Costs AT&T To Spin Off DirecTV In $16.3B Venture With TPG Steel Dynamics Bumps Up Q1 Dividend; Street Remains Cautiously Optimistic